BOARD OF DIRECTORS LIPUM

Management team: Dr Einar Pontén

MSc Ulf Björklund, Chairman of the Board
Born: 1956 | Entered: 2016
Total shares with related parties: 12 955
TO1: 480

Mr. Björklund is M.Sc. in Pharmacy with more than 30 years of experience from the pharmaceutical industry, which ranges from pharmaceutical discovery and development of new drugs to diagnostics – from research to marketing. Prior engagements include CEO of Aprea (oncology) and CEO of OxyPharma (autoimmune diseases). Before that he held several positions within Pharmacia covering clinical research in many therapeutic areas of which the majority of the time in managerial positions. Mr. Björklund has experience in managing partner collaborations, financing and dealing with regulatory authorities in Europe and US. Mr. Björklund currently serves as board member in TikoMed AB and MedicaNatumin AB. Independent in relation to the company, the management and major shareholders.
LinkedIn profile »

Management team: Dr Einar Pontén

Professor Olle Hernell, board member and co-founder
Born: 1945 | Entered: 2010
Total shares with related parties: 318 300
TO1: 500

Olle Hernell, MD, PhD,  Professor of pediatrics and former head of Pediatrics at the Department of Clinical Sciences, Umeå University. He has more than 30 year experience as senior consultant, responsible for pediatric gastroenterology, hepatology and nutrition. He discovered the bile salt-stimulated lipase (BSSL) in human milk and is internationally well known for his BSSL research, clarifying its structure, characteristics and physiological function in fat digestion and its role in inflammation. Prof. Hernell´s  research spans from basic science to clinical trials, including a recent phase III RCT conducted by Swedish Orphan Biovitrum (Sobi). He has published close to 300 peer reviewed scientific papers, trained more 20 PhD students, served on/or chaired many national and international committees and working groups. He is an inventor on several patents and has long experience of collaboration with industry. Dependent in relation to the company, the management and major shareholders.
LinkedIn profile »

Management team: Dr Einar Pontén

Dr. Kristian Sandberg, board member
Born: 1961 | Entered: 2019
Total shares with related parties: –
Dr Kristian Sandberg is an associate professor in immunology and an experienced leader in the pharmaceutical industry’s research and development. Sandberg has over 20 years’ experience from AstraZeneca in various functions within R&D, primarily with project leader responsibilities. He has experiences from the development of both protein and conventional small molecule based drugs from concept to clinical Phase II studies, in the field of neuroscience as well as respiratory, inflammatory and autoimmune diseases. Sandberg is active as an affiliated researcher to the Karolinska Institute and has had various assignments within the Foundation for Strategic Research. Since 2015, Sandberg holds the position as Director for the Drug Discovery Platform at Science for Life Laboratories (SciLifeLab) at Uppsala University. In addition to this responsibility, he was project leader for the development and optimization of a therapeutic antibody directed towards bile salt-stimulated lipase (BSSL). Sandberg sits on the board of Toleranzia AB, listed on the Spotlight Market. Sandberg is also a co-founder and board member of PharmaPrecision AB. Independent in relation to the company, the management and major shareholders.
LinkedIn profile »

Management team: Dr Einar Pontén

Åsa Hansdotter, board member
Born: 1974 | Entered: 2021
Total shares with related parties: –
Åsa Hansdotter is an attorney-at-law and partner of the business law firm HWF Advokater AB in Helsingborg. She works with company and equity capital markets law, Swedish and international M&A and further handles corporate commercial matters as external legal counsel for listed and non-listed companies within the industry and life science sectors among others. During 2001-2017, Åsa was with Mannheimer Swartling, 2010-2017 as a partner. Åsa is a board member in i.a. Dizlin Pharmaceuticals AB, P Capital Partners AB and the Swedish Chamber of Commerce for Russia & CIS. Independent in relation to the company, the management and major shareholders.
LinkedIn profile »

Management team: Dr Einar Pontén

Dr Ingemar Kihlström, board member
Born: 1952 | Entered: 2021
Total shares with related parties: –
Dr Ingemar Kihlström has doctoral degree in physiology/toxicology from Uppsala University. He has extensive experience in drug development and the Life Science industry. Previously Dr Kihlström worked with research and development and business development at both Astra AB and Pharmacia AB followed by a career as pharmaceutical analyst in the finance industry at Swedbank, Aros Securities and ABG Sundal Collier. Over the years, he has worked both as Chairman and Director on the board of more than thirty companies and Dr Kihlström is currently on the board of several listed companies, mainly on Nasdaq First North in Stockholm. Independent in relation to the company, the management and major shareholders.
LinkedIn profile »

ABOUT US